Sumuary Interferon alpha-2a (IFN-a) and fohinc acid (FA) (491/.) no change of disease (NC). Thirteen patients (23%) had progressive disease (PD). The median survival time was 10 months for all patients, 22 months for patients with partial remission and 5 months for patients with progressive disease. Many patients with tumour-related pain whose tumours were affected in terms of PR, MR, NC were free of pain during treatment with this regimen (22/36 patients). The common toxicities observed were fever (56%), nausea (37%) and diarrhoea (33%). These data suggest that biochemical modulation of 5-FU with FA and IFN-a has some positive effects in the treatment of pancreatic cancer of moderate toxicity.
Pancreatic cancer is often diagnosed when the disease is far advanced. Only a minority of patients can be cured by surgery after early diagnosis. Patients with inoperable pancreatic cancer have a limited survival rate, averaging only 3-4 months (Warshaw et al., 1992; Brennan et al., 1993) . The results of chemotherapy for pancreatic carcinoma have generally been disappointing, and only a few agents appear to have a proven therapeutic effect. 5-Fluorouracil is the most evaluated and commonly used single agent. Response rates achieved range from 10 to 20%. Other substances, such as mitomycin, ifosfamide or epirubicine, do not induce greater response rates. Furthermore, combination therapies are not superior to single-agent 5-FU and cause more sideeffects (Cullinan et al., 1990; Kelsen et al., 1991; Wils, 1991; Warshaw et al., 1992; Brennan et al., 1993) . However, 5-FU alone does not improve survival rates, and to date chemotherapy must be considered experimental in this disease. Attempts to improve the therapeutic efficacy of 5-FU are focused on the principles of 'biomodulation' of the cellular effects of its metabolites. Preclinical studies with biomodulators such as folinic acid or IFN-a have shown an augmentation of the 5-FU cytotoxicity against tumour cells by increasing the 5-FU-induced inhibition of key enzymes of de novo DNA synthesis. Folinic acid enhances the 5-FUinduced inhibition of thymidilate synthetase and IFN-a inhibits thymidine kinase (Ernstoff et al., 1989 , Grem et al., 1992 ; Van der Wilt et al., 1992) . Considering that some clinical trials on the biomodulation of 5-FU with IFN-a and/or folinic acid in colorectal carcinoma have been successful, similar therapy regimens seem to be worth testing in pancreatic cancer (Petrelli et al., 1987 (Petrelli et al., , 1989 Wadler et al., 1989; Bukowski et al., 1991; Piedbois et al., 1992; Sobrero et al., 1992) .
We therefore conducted a pilot study to evaluate the toxi- (Petrelli et al., 1987 (Petrelli et al., , 1989 (Kaplan et al., 1958 staed. Interestingly, 3/9 patients responded again during the second course of therapy (1/9 PR; 1/9 MR; 1/9 NC). (Table II; Figure 2). There was no signnt survival difference between patients with locoregional diseas only (8 months) and patients with distant metastases (10 months).
Toxicity
Toxicity data are presented in Table IV for al eligible paients with at least 4 weeks follow-up (n = 57). The most prominent toxicity associated with 5-FU was nausea (21/57; 37%), which was suppressed in all patients by antemetic treatment during the following cyces of therapy. Diarrho, observed in 19/57 patients (33%), was a common gstrointestinal side-effect, which disappeared regularly after dose reduction of 5-FU. Stomatitis was a rare sde-effect (1/57 patients) and severe myekouppression did not occur. The most frequently observed side-effects caused by interferon-a were fever (56%) and fatigue (28%). Fatal treatment-relate neurological disorders described previously were not observed (Wadler et al., 1989) . However, it cannot be formally ruled out that one observed stroke may have been induced by IFN-a. In this and two other patients the treatment had to be interrupted because of intolerable ide-effects:
one patient experienced worsening of her asthma and a second icreased severity of angina pectoris. No treatmentrelated death was encountered.
A focus in the chemotherapy of advaned pancreatic cancer has been to maxmise the efficacy of 5-FU through biomodulation. Wils, 1991) .
Other trials using IFN-a or/and folinic acid in advanced pancreatic cancer have shown marginal activity with respect to response rates and survival (Crown et al., 1991; DeCaprio et al., 1991; Pazdur et al., 1992; Scheithauer et al., 1992; Weinerman and McCormick, 1992; Rubin et al., 1992) . Patients with pancreatic carcinoma frequently present with a low performance status, signs of malabsoon owing to panceatic excrory dysfimction, weight oss, abdominal pain, bowel dysmotility and obstrucive jaundice. Because of this constellation of symptoms, most patients do not tolerate sidefects of intensive chemotherapy, but require pallative therapy. Hence, criteria for successfl therapy must be not only reponse rate and survival, but also treatment-related toxicity and quality of life. The data from our study suggest that combination of 5-FU with FA and IFN-a has moderate sdeffects and may alleviate or abolsh pre-eisting tumourrelated pain. In this respect study patients experienced a palliative benefit from this therapy schedule.
The trnds observed,in this phase II trial are promising, but further clnical trials are necesary to confirm our prelminary rsults. To date it is still unclear if 5-FU/FA/ IFN-a renders any advantage over 5-FU alone or in combination with FA in the treatment of pancreatic cancer. We have started a randomised trial in order to compare the effectiveness of the combination '5-FU/FA/IFN-c' with '5-FU/FA' alone. This phase III trial will evaluate study parameters regarng quality of life besides response rate and survival. 
